Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma
10.3760/cma.j.cn112138-20240805-00492
- VernacularTitle:经动脉化疗栓塞术联合信迪利单抗及贝伐珠单抗类似物治疗不可切除肝细胞癌的有效性和安全性研究
- Author:
Hao YANG
1
;
Jintao HUANG
1
;
Di HU
1
;
Binyan ZHONG
1
;
Jian SHEN
1
;
Xiaoli ZHU
1
Author Information
1. 苏州大学附属第一医院介入科，苏州 215000
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Chemoembolization, therapeutic;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Internal Medicine
2025;64(2):134-141
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular careinoma (uHCC).Methods:The clinical data of 64 patients with unresectable HCC, who were admitted to the First Affiliated Hospital of Soochow University between January 2021 and December 2023, were retrospectively analyzed. The patients were divided into a combination group ( n=43, receiving TACE combined with sintilimab and bevacizumab biosimilar) and control group ( n=21, receiving only sintilimab and bevacizumab biosimilar). Survival curves were drawn by Kaplan-Meier method, and the median overall survival (mOS) and median progression-free survival (mPFS) were compared between the two groups. According to the mRECIST criterion, the objective response rate (ORR) and disease control rate (DCR) were compared between the two groups. The occurrences of adverse events in both groups were recorded. Results:The mOS and mPFS in the combination group were 22.3 months and 12.4 months, respectively, which in the control group was 11.6 months and 6.4 months, respectively. The differences between the two groups were statistically significant ( P=0.001 and P=0.002). The ORR and DCR in the combination group were 62.8% and 95.3% respectively, which were significantly higher than 19.0% and 57.1% respectively in the control group (all P<0.01). No statistically significant difference in the incidence of severe adverse events existed between the two groups ( P=0.518). Conclusion:TACE combined with sintilimab and bevacizumab biosimilar has efficacy and safety than sintilimab and bevacizumab biosimilar alone.
